CTi Biopharma Corp (NASDAQ:CTIC)

Data as of Oct 21
 -0.02 / -0.84%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

CTI BioPharma Corp. operates as a biopharmaceutical company, which is focused on the acquisition, development, and commercialization of less toxic and more effective ways to treat cancer. Its products include Pixuvri, OPAXIO, Brostallicin and Bisplatinates. Pixuvri is a novel anthracycline derivative used for the treatment of hematologic malignancies and solid tumors. The company was founded by James A. Bianco, Jack W. Singer and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Contact Information

CTI BioPharma Corp.
3101 Western Avenue
Seattle Washington 98121
P:(206) 282-7100
Investor Relations:
(206) 272-4343



Individual stakeholders2.02%
Mutual fund holders15.89%
Other institutional12.93%

Top Executives

James A. BiancoPresident, Chief Executive Officer & Director
Lou A. BiancoExecutive Vice President-Finance & Administration
Jack W. SingerDirector & EVP-Global Medical Affairs
Matthew J. PlunkettExecutive Vice President-Corporate Development
Monique GreerSVP-Investor Relations & Corporate Communications

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.